Contact
Please use this form to send email to PR contact of this press release:
ADAA’s 2019 Conference to Feature Sessions on Ketamine, the FDA-Approved Nasal Spray for Treatment Resistant Depression
TO:
Lise Bram
Anxiety and Depression Association of America (ADAA)
+1 240-485-1016